Accessibility Menu
TScan Therapeutics logo

TScan Therapeutics(NASDAQ) TCRX

Market Cap$48.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-93%
5 Year-92%
1 Year-57%
1 Month-31%
$0.73
-2.38%
-0.02Today
After hours$0.73-$0.00 (-0.01%)
TScan Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.742026-07-31
TScan Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.42%USD 0.792026-07-24
1 month-30.56%USD 1.072026-07-01
3 month-39.1%USD 1.222026-05-01
Year to date-25.7%USD 1.002025-12-31
1 year-57.3%USD 1.742025-07-31
3 year-66.07%USD 2.192023-08-01
5 year-92.34%USD 9.702021-07-30
Since inception-92.92%USD 10.502021-07-16

TScan Therapeutics Financials at a Glance

Market Cap

$48.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.14M

Net Income (TTM)

-$124.31M

EPS (TTM)

-$0.96

P/E Ratio

-0.78

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$0.73

Volume

438,301.181

Open

$0.76

Previous Close

$0.72

Daily Range

$0.72 - $0.78

52-Week Range

$0.72 - $2.57

Estimated Earnings Date

Aug 11, 2026

TCRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TScan Therapeutics

TScan develops cell therapies to help people with cancer and infectious diseases. Its treatments aim to prevent cancer relapse and target solid tumors. The company also works on vaccines for viruses like COVID-19.

Therapies in a Nutshell: What TScan Sells

  • TCR-T Cell Therapies: Engineered immune cells designed to find and attack cancer cells; 100% of revenue from collaboration agreements, not product sales.
  • Hematologic Cancer Therapies: TSC-100 and TSC-101 target blood cancers after stem cell transplants; aim to prevent relapse.
  • Solid Tumor Therapies: TSC-200 series targets different proteins found in solid tumors; designed for personalized treatment.
  • Multiplex TCR-T (T-Plex): Combines up to three therapies for each patient to address tumor diversity.
  • Infectious Disease Vaccines: Early-stage vaccines for viruses, including SARS-CoV-2 (COVID-19).
  • Research Collaborations: Revenue from partnerships with companies like Amgen and Novartis for discovering new treatment targets.

Growth Spurts and Strategic Moves

  • Signed a collaboration with Novartis in 2021 for cancer antigen discovery.
  • Entered a partnership with Amgen in 2023 for Crohn’s disease research, receiving a $30 million upfront payment.
  • Expanded its ImmunoBank and launched multiplex TCR-T (T-Plex) clinical programs in 2024.
  • Increased manufacturing and research facilities at 830 Winter Street in 2024.
  • Raised capital through public and direct offerings in 2023 and 2024 to fund operations.

What Makes TScan Stand Out (Without the Lab Coat)

TScan uses proprietary technology to create personalized cancer therapies. Its ImmunoBank stores a wide range of immune cell receptors for different patients. The company focuses on both blood cancers and solid tumors, aiming for flexible treatment options.

Five Things You Need to Know

  • Revenue was $3.08 million in Q2 2025, up 473.9% from Q2 2024.
  • Net loss was $(36.95) million in Q2 2025, 16.7% greater than in Q2 2024.
  • Cash and marketable securities totaled $218.0 million as of June 30, 2025.
  • All revenue comes from research collaborations, not product sales.
  • Operating expenses rose 20.4% year-over-year in Q2 2025, mainly from research costs.

Bottom Line

TScan is building a pipeline of cell therapies and vaccines through partnerships and research. The company remains pre-commercial, with all revenue from collaborations and ongoing investment in development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

139

CEO

Gavin MacBeath, PhD

Website

www.tscan.com

Headquarters

Waltham, MA 02451, US

TCRX Financials

Key Financial Metrics (TTM)

Gross Margin

92.41%

Operating Margin

-1408.73%

Net Income Margin

-1360.61%

Return on Equity

-91.94%

Return on Capital

-62.51%

Return on Assets

-61.54%

Earnings Yield

-1.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$48.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.35M

Volume

438.30K

Avg. Volume

704.77K

Financials (TTM)

Gross Profit

$8.44M

Operating Income

-$128.70M

EBITDA

-$118.65M

Operating Cash Flow

-$122.01M

Capital Expenditure

-$2.95M

Free Cash Flow

-$124.96M

Cash & ST Invst.

$128.06M

Total Debt

$92.54M

TScan Therapeutics Performance Analysis

TScan Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 13,535,00033.5%
20232023-12-31USD 21,049,00055.5%
20242024-12-31USD 2,816,000-86.6%
20252025-12-31USD 10,325,000266.7%
TScan Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3041.7%
Q32025-09-30-18.4%
Q42025-12-312.2%
Q12026-03-31-61.7%
TScan Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.75-34.0%
20232023-12-31USD -1.36-50.6%
20242024-12-31USD -1.14-16.3%
20252025-12-31USD -1.00-12.2%
TScan Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7.7%
Q32025-09-30N/A
Q42025-12-3135.7%
Q12026-03-31-22.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$982.00K

-54.8%

Gross Profit

$289.00K

-86.7%

Gross Margin

29.43%

N/A

Market Cap

$48.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$341.94K

N/A

Employees

142

N/A

Net Income

-$28.67M

+16.0%

EBITDA

-$27.28M

+16.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$128.06M

-49.1%

Total Debt

$92.54M

-4.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$85.10M

-7.6%

Short Term Debt

$7.44M

+49.6%

Return on Assets

-61.54%

N/A

Return on Invested Capital

-70.71%

N/A

Free Cash Flow

-$24.35M

+37.8%

Operating Cash Flow

-$24.28M

+35.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PMVPPMV Pharmaceuticals, Inc.
$1.12+0.90%
NTRBNutriband Inc.
$2.81-1.40%
LITSLite Strategy, Inc.
$0.98+1.84%
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.56+4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About TCRX

What is the current price of TScan Therapeutics?

TScan Therapeutics is trading at $0.72 per share.

What is the 52-week range for TScan Therapeutics?

Over the past 52 weeks, TScan Therapeutics has traded between $0.72 and $2.57.

How much debt does TScan Therapeutics have?

As of the most recent reporting period, TScan Therapeutics reported total debt of $92.54M.

How much cash does TScan Therapeutics have on hand?

TScan Therapeutics reported $128.06M in cash and cash equivalents in its most recent financial results.

What is TScan Therapeutics’s dividend yield?

TScan Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services